
Overview
Healthcare company's preliminary Q4 revenue rises, cash flow positive for second time in 2025
Company expects Q4 gross margin to rise to 22%, up from 14% in Q3
Outlook
Company focuses on revenue growth, profitability, and portfolio diversification for 2026
Result Drivers
REVENUE INCREASE - Rockwell Medical reported a considerable increase in preliminary Q4 revenue, exceeding analyst expectations
GROSS MARGIN IMPROVEMENT - preliminary Q4 gross margin rose to 22%, up from 14% in Q3, due to improved operational efficiencies and reduced expenses
CASH FLOW POSITIVE - Company achieved positive cash flow from operations in Q4, marking the second positive quarter in 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $18.60 mln | $16.55 mln (2 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Rockwell Medical Inc is $3.75, about 291.7% above its January 16 closing price of $0.96
Press Release: ID:nBw205KS8a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.